Cargando…

Evolution by innovation as a driving force to improve TCR-T therapies

Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges o...

Descripción completa

Detalles Bibliográficos
Autor principal:	Schendel, Dolores J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552759/ https://www.ncbi.nlm.nih.gov/pubmed/37810959 http://dx.doi.org/10.3389/fonc.2023.1216829

Ejemplares similares

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity
por: Schendel, Dolores J., et al.
Publicado: (2013)

TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022)

Small extracellular vesicle DNA-mediated horizontal gene transfer as a driving force for tumor evolution: Facts and riddles
por: Valcz, Gábor, et al.
Publicado: (2022)

Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability
por: Zavacka, Kristyna, et al.
Publicado: (2021)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Strategies in biomedical data science: driving force for innovation
por: Etchings, Jay
Publicado: (2017)

RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy
por: Zhigalova, Ekaterina A., et al.
Publicado: (2020)

Delegation to automaticity: the driving force for cognitive evolution?
por: Shine, J. M., et al.
Publicado: (2014)

Autoimmunity as a Driving Force of Cognitive Evolution
por: Nataf, Serge
Publicado: (2017)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges
por: Kang, Synat, et al.
Publicado: (2022)

TCR mimic compounds for pHLA targeting with high potency modalities in oncology
por: Gerber, Hans-Peter, et al.
Publicado: (2022)

Immune Checkpoints and Innovative Therapies in Glioblastoma
por: Romani, Massimo, et al.
Publicado: (2018)

Public-private partnerships as driving forces in the quest for innovative medicines
por: Goldman, Michel, et al.
Publicado: (2013)

Editorial: Discovery of small molecule lead compounds: A driving force to unravel new anticancer targets and mechanisms
por: Zhang, Yan, et al.
Publicado: (2023)

The evolution of the ‘QUAD’: driving forces, impacts, and prospects
por: Wei, Zongyou
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

An innovative and affordable quantitative assessment of human TCR repertoire
por: Amoriello, Roberta, et al.
Publicado: (2020)

Metaomics in Clinical Laboratory: Potential Driving Force for Innovative Disease Diagnosis
por: Wang, Liang, et al.
Publicado: (2022)

Improving TCR Gene Therapy for Treatment of Haematological Malignancies
por: Nicholson, Emma, et al.
Publicado: (2012)

Force Measurements of TCR/pMHC Recognition at T Cell Surface
por: Puech, Pierre-Henri, et al.
Publicado: (2011)

Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
por: Deshpande, Anagha, et al.
Publicado: (2022)

tRNAs as a Driving Force of Genome Evolution in Yeast
por: Guimarães, Ana Rita, et al.
Publicado: (2021)

Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
por: Sun, Yimo, et al.
Publicado: (2021)

Pediatric Medulloblastoma – Update on Molecular Classification Driving Targeted Therapies
por: DeSouza, Ruth-Mary, et al.
Publicado: (2014)

Regulation Networks Driving Vasculogenic Mimicry in Solid Tumors
por: Hernández de la Cruz, Olga N., et al.
Publicado: (2020)

Transcriptional abundance is not the single force driving the evolution of bacterial proteins
por: Wei, Wen, et al.
Publicado: (2013)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

Domain-swapped T cell receptors improve the safety of TCR gene therapy
por: Bethune, Michael T, et al.
Publicado: (2016)

Spatio-temporal evolution and driving forces of habitat quality in Guizhou Province
por: Xie, Bo, et al.
Publicado: (2023)

Reverse Evolution: Driving Forces Behind the Loss of Acquired Photosynthetic Traits
por: de Castro, Francisco, et al.
Publicado: (2009)

The driving force of prophages and CRISPR-Cas system in the evolution of Cronobacter sakazakii
por: Zeng, Haiyan, et al.
Publicado: (2017)

Spatiotemporal Evolution and Driving Forces of Vegetation Cover in the Urumqi River Basin
por: Mamattursun, Azimatjan, et al.
Publicado: (2022)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms
por: Gonzalez-Vicent, Marta, et al.
Publicado: (2022)

Breaking Bottlenecks for the TCR Therapy of Cancer
por: Gaissmaier, Lena, et al.
Publicado: (2020)

HLA Class I Restriction as a Possible Driving Force for Chikungunya Evolution
por: Tong, Joo Chuan, et al.
Publicado: (2010)

Editorial: Innovations in surgical oncology
por: Aramini, Beatrice, et al.
Publicado: (2023)

A driving force.
por: Holzman, D
Publicado: (1997)

Optimized Conformal Total Body Irradiation Among Recipients of TCRαβ/CD19-Depleted Grafts in Pediatric Patients With Hematologic Malignancies: Single-Center Experience
por: Kobyzeva, Daria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_662u64cbujk414t94b6m4gt0su